Chronic Malignancies Working Party (CMWP)

Chair: Donal McLornan
Secretaries: Joanna Drozd-Sokolowska & Kavita Raj
**Data management:** Linda Koster, Laurien Baaij, Joe Tuffnell
Statisticians: Dirk-Jan Eikema, Luuk Gras, Simona Iacobelli
Nurse: Chiara Giacon

CML

Chair: Yves Chalandon, Vice Chair: Guillermo Ortí, Hugues De Lavallade & Chris Armstrong

Number of first allogeneic transplants for CML registered at EBMT per year

Related — Mismatched related — Unrelated — Total allograft

CLL

Chair: Olivier Tournilhac, Vice Chair: Michel van Gelder

Number of first allogeneic transplants for CLL registered at EBMT per year

Related — Mismatched related — Unrelated — Total allograft

PCD

Chair: Patrick Hayden, Vice Chair: Meral Beksac & Inas El-Najjar

Number of autologous transplants for MM registered by EBMT per year

1st auto — 2nd or later auto

PCD CAR-T

Chair: Nico Gagelmann, Vice Chair: Laurent Garderet

Number of CAR-T for MM registered at EBMT per year

MDS

Chair: Marie Robin, Vice Chair: Christof Scheid & Carmelo Gurnari & Francesco Onida

Number of first allogeneic transplants for MDS registered at EBMT per year

Related — Mismatched related — Unrelated — Total allograft

MDS/MPN

Chair: Marie Robin, Vice Chair: Christof Scheid & Carmelo Gurnari & Francesco Onida

Number of first allogeneic transplants for MDS/MPN registered at EBMT per year

Related — Mismatched related

MPN

Chair: Juan Carlos Hernández-Boluda, Vice Chair: Tomasz Czerw & Nicola Polverelli & Giorgia Battipaglia

Number of first allogeneic transplants for MPN registered at EBMT per year

Related — Mismatched related — Unrelated — Total allograft

*Lower number of HCT/CAR-T possibly due to a back-log in reporting.
Data cut-off point for graphs: February 2026

cmwp@ebmt.org

Ongoing studies - highlights

- Development of a prognostic model for survival after allo-HCT in patients with MDS using machine learning (Donal P. McLornan, Carmelo Gurnari, Adrián Mosquera Orgueira, Marie Robin)
- Development of a prognostic model for estimation of survival after allo-HCT in patients CMML utilizing Machine Learning (Marie Robin, Adrián Mosquera Orgueira, Francesco Onida, Carmelo Gurnari, Donal P. McLornan)
- Del 17p MM patients who underwent auto-HCT in EBMT centres between 2016 and 2022 (Patrick Hayden)
- Analysis of Characteristics, Outcome and Risk Factors of Patients with Myelodysplastic Syndrome undergoing a Second Allogeneic Transplantation after Relapse from First allo-HCT (Giuliano Filippini Velazquez, Christoph Schmid)
- Outcomes of Plasma Cell Myeloma Patients with t(4;14) who underwent auto-HCT (Joanna Drozd-Sokolowska, Patrick Hayden)

Key Publications 2025

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT – *Gurnari et al. Blood 2025; 145 (18): 1987–2001.*

Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT – *Polverelli et al. Blood 2025; 145 (22): 2561–2573.*

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis – *Hernández-Boluda Blood 2025; 145 (26): 3139–3152.*

Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT – *Loukili Bone Marrow Transplant 60, 1487–1495 (2025).*

Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT - *Hernández-Boluda American Journal of Hematology 100, no. 11 (2025): 2028–2039.*

Rome meeting 2025

www.ebmt.org